ABBV ▲ +0.5% - AbbVie Inc. $ABBV - AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Children with Active Polyarticular Juvenile Idiopathic Arthritis AbbVie rose 0.5% following European Commission approval of RINVOQ for treating children with active polyarticular juvenile idiopathic arthritis, expanding the drug's market reach into a new pediatric indication across Europe. 22-SEP-2026 02:00 AM ET